OXFORD, OH and DENVER, CO, Aug. 29, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions…


Previous articleWesana Announces Second Quarter 2022 Financial Results
Next articlePT351 – Seth Rosenberg – The Trauma In Being Arrested and The Injustice of the Drug War